Medical Oncology
Prof. Dr. Mutlu Demiray
-> Oncology:
• Solid Tumor Oncology
• Brain Cancer and Tumors
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Bladder Cancer
• Kidney Cancer
• Liver Cancer
• Thyroid Cancer
• Melanoma
-> Internal Medicine:
• Basic Principles of Internal Medicine
• Managing Cancer-Related Complications
• Supportive Therapy for Cancer Patients
• Chemotherapy and Its Side Effects
• Hormonal Therapy for Cancer
• Radiology and Imaging:
• Interpretation of Imaging (CT, MRI, PET)
• Interventional Radiological Procedures for Cancer Treatment (Radiofrequency Ablation, Embolization)
-> Pathology:
• Interpretation of Cancer Pathology Reports
• Molecular Pathological Techniques for Cancer Diagnosis and Prognosis
-> Surgery:
• Principles of Surgical Oncology
• Consultations with Surgical Oncologists for Treatment Planning
• Postoperative Care for Cancer Patients
-> Radiation Therapy:
• Principles of Radiation Therapy for Cancer Treatment
• Collaboration with Radiation Oncologists for Combined Treatment
-> Pharmacology:
• Pharmacokinetics and Pharmacodynamics of Anticancer Drugs
• Designing Clinical Trials and Participating in Clinical Trials of Anticancer Drugs
Education:
Medical School Graduated From and Year:
- Akdeniz University Faculty of Medicine, 1995
Place and Year of Specialization Training:
- Uludağ University Faculty of Medicine, 2005
Internal Medicine, 2000
Medical Oncology, 2004
Academic Appointments:
- Uludağ University (Assistant Professor), 2004-2006
- Ali Osman Sönmez Oncology Hospital (Associate Professor), 2006-2007
- Medical Park Bursa Hospital (Associate Professor), 2007-2010
- Istanbul Italian Hospital (Associate Professor), 2010-2011
- OSM Middle East Hospital (Associate Professor), 2011-2013
- Germany Integrative Oncology Training, Private Practice (Associate Professor), 2013-2014
- Medicana Health Group (Professor), 2014-Present
A1. DNA Repair Deficiency: A Series of 8 Patients. Integr Cancer Ther. 2020 Jan-Dec;19: doi: 10.1177/1534735420969812. PMID: 33150793.
A2. Bahadori F, Demiray M. Management of extravasation of oxaliplatin by mimicking its biotransformation. Clin Transl Oncol. 2018 Oct;20(10):1353-1357. doi: 10.1007/s12094-018-1854-z. Epub 2018 Apr 27. PMID: 29704231.
A3. Sahinbas H, Rosch M, Demiray M. Temperature measurements in a capacitive system of deep loco-regional hyperthermia. Electromagn Biol Med. 2017;36(3):248-258. doi: 10.1080/15368378.2017.1307221. Epub 2017 Apr 27. PMID: 28448752.
A4. Bahadori F, Demiray M. A Realistic View on "The Essential Medicinal Chemistry of Curcumin". ACS Med Chem Lett. 2017 Sep 14;8(9):893-896. doi: 10.1021/acsmedchemlett.7b00284. PMID: 28947929; PMCID: PMC5601379.
A5. Demiray M, Sahinbas H, Atahan S, Demiray H, Selcuk D, Yildirim I, Atayoglu AT. Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report. Complement Ther Med. 2016 Aug;27:108-13. doi: 10.1016/j.ctim.2016.06.009. Epub 2016 Jul 1. PMID: 27515884.
A6. Arican A, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014 Oct;22(10):2629-34. doi: 10.1007/s00520-014-2253-9. Epub 2014 Apr 22. PMID: 24752566; PMCID: PMC4153980.
A7. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, Manavoglu O. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006 Nov;24(7):669-76. doi: 10.1080/07357900600981307. PMID: 17118776.
A8. Demiray M, Kurt E, Evrensel T, Kanat O, Arslan M, Saraydaroglu O, Ercan I, Gonullu G, Gokgoz S, Topal U, Tolunay S, Tasdelen I, Manavoglu O. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer Invest. 2005;23(5):386-91. doi: 10.1081/cnv-67133. PMID: 16193637.
A9. Demiray M, Gulten M, Manavoglu O, Evrensel T, Ulukaya E, Yerci O, Kanat O, Kurt E, Arslan M, Gonullu G, Demiray H, Gulten T, Memik F. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study. Hepatogastroenterology. 2004 Sep-Oct;51(59):1531-5. PMID: 15362794.
A10. Gulten T, Tokyay N, Demiray M, Gulten M, Ercan I, Evke E, Sardas S, Karakaya AE. The role of triple therapy, age, gender and smoking on the genotoxic effects of Helicobacter pylori infection. J Int Med Res. 2002 Jul-Aug;30(4):380-5.
A11. Arslan M, Evrensel T, Kurt E, Demiray M, Ercan I, Kanat O, Ozkan A, Manavoglu O. Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients. Neoplasma. 2005;52(1):43-5.
A12. Arslan M, Evrensel T, Kurt E, Demiray M, Gonullu G, Kanat O, Manavoglu O. Comparison of clinical outcomes of different erythropoietin usage strategies. Tumori. 2004 Jul-Aug;90(4):394-8.
A13. Kanat O, Evrensel T, Kurt E, Demiray M, Gonullu G, Arslan M, Manavoglu O. Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study. Tumori. 2004 Mar-Apr;90(2):192-5.
A14. Kanat O, Evrensel T, Manavoglu O, Demiray M, Kurt E, Gonullu G, Kiyici M, Arslan M. Single agent irinotecan as second-line treatment for advanced gastric cancer. Tumori. 2003 Jul-Aug;89(4): 405-7.
A15. Kanat O, Adim S, Evrensel T, Yerci O, Ediz B, Kurt E, Demiray M, Gonullu G, Arslan M, Manavoglu O.Prognostic value of nm23 in gastrointestinal stromal tumors. Med Oncol. 2004; 21(1): 53-8.
A16. Kurt E, Sezgin C, Evrensel T, Yalcinkaya U, Kanat O, Veral A, Demiray M, Arslan M, Karabulut M, Ercan I, Goker E, Manavoglu O. Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary carcinoma Int J Clin Pract. 2005 May;59(5):537-43.
A17. Kanat O, Evrensel T, Baran I, Coskun H, Zarifoglu M, Turan OF, Kurt E, Demiray M, Gonullu G, Manavoglu O. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Med Oncol. 2003;20(3):237-45.
A18. Kanat O, Evrensel T, Adim SB, Yavascaoglu I, Kurt E, Demiray M, Gonullu G, Manavoglu O. Small cell carcinoma of the urinary bladder. A clinicopathologic study of five cases. Tumori. 2003 MayJun;89(3):328-30.
A19. Alper E, Gurel M, Evrensel T, Ozkocaman V, Akbunar T, Demiray M.99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphy. Nucl Med Commun. 2003 May;24(5):537-42.
A20. Kanat O, Evrensel T, Demiray M, Kurt E, Gonullu G, Arslan M, Manavoglu O, Ozkan A. Cisplatin plus etoposide in advanced non-small cell lung cancer patients age of 70 years or older. Lung Cancer. 2003 Aug;41(2):233-4.
A21. Kanat O, Evrensel T, Kurt E, Arslan M, Demiray M, Aker S, Manavoglu O. Successful treatment of thymoma-associated erythroid hypoplasia and thrombocytopenia with paclitaxel. Clin Oncol (R Coll Radiol). 2005 Feb;17(1):68
A22. Tasdelen I, Gokgoz S, Paksoy E, Yerci O, Cetintas SK, Demiray M, Samsa V. Acquired lymphangiectasis after breast conservation treatment for breast cancer: report of a case. Dermatol Online J. 2004 Jul 15;10(1):9.
A23. Ozkan K, Turkkan E, Ender K, Mutlu D, Murat A, Nalan B, Abdulmecit Y, Osman M. 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients. Indian J Cancer. 2005 Apr-Jun;42(2):85-8.